Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Forecast Score | Market Cap | Price | Price Target | Upside/Downside | Consensus | Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd | 100 | $176.38M | $17.79 | $26.00 | 46.15% | Buy | 1 | 52.48% | 70.43% | 58.63% | 52.43% |
| VCEL | Vericel Corp | 89 | $2.45B | $52.94 | $42.00 | -20.66% | Strong Buy | 6 | 26.77% | 103.97% | 88.94% | 58.97% |
| EXEL | Exelixis Inc | 89 | $5.28B | $16.85 | $33.00 | 95.85% | Buy | 7 | 22.71% | 74.25% | 26.07% | 22.75% |
| HALO | Halozyme Therapeutics Inc | 89 | $5.88B | $41.33 | $52.00 | 25.82% | Buy | 3 | 31.18% | 38.49% | 730.25% | 51.07% |
| CDMO | Avid Bioservices Inc | 89 | $1.57B | $25.65 | $28.00 | 9.16% | Strong Buy | 3 | 29.01% | 137.75% | 66.81% | 19.56% |
| BNTX | BioNTech SE | 78 | $79.30B | $328.35 | $173.80 | -47.07% | Hold | 7 | 112.93% | 418.96% | -53.12% | -31.43% |
| MRNA | Moderna Inc | 78 | $141.98B | $353.60 | $187.36 | -47.01% | Buy | 13 | 53.49% | 77.07% | -18.47% | -5.58% |
| BDSI | Biodelivery Sciences International Inc | 78 | $370.56M | $3.76 | $5.50 | 46.28% | Buy | 1 | 15.97% | 45.01% | 88.12% | 39.62% |
| INCY | Incyte Corp | 67 | $17.01B | $77.35 | $89.67 | 15.92% | Buy | 6 | 14.33% | 31.37% | 59.90% | 44.63% |
| ABCM | Abcam plc | 67 | $4.26B | $18.91 | $22.00 | 16.34% | Hold | 3 | 19.46% | 85.61% | 15.87% | 9.83% |
| UTHR | UNITED THERAPEUTICS Corp | 56 | $8.15B | $181.93 | $227.20 | 24.88% | Strong Buy | 5 | 10.85% | 23.77% | 26.21% | 19.45% |
| RPRX | Royalty Pharma plc | 56 | $23.19B | $38.20 | $50.50 | 32.20% | Strong Buy | 2 | 4.03% | 32.62% | 23.70% | 14.65% |
| VNDA | Vanda Pharmaceuticals Inc | 56 | $907.46M | $16.31 | $18.00 | 10.36% | Buy | 2 | 10.99% | 32.83% | 25.78% | 21.86% |
| JAZZ | Jazz Pharmaceuticals plc | 44 | $9.65B | $169.52 | $201.58 | 18.91% | Buy | 12 | 17.25% | 19.44% | 17.02% | 9.57% |
| CORT | Corcept Therapeutics Inc | 44 | $2.41B | $20.77 | $22.33 | 7.53% | Buy | 3 | 14.36% | 16.13% | 38.59% | 35.48% |
| LGND | Ligand Pharmaceuticals Inc | 44 | $1.89B | $113.51 | $221.25 | 94.92% | Strong Buy | 4 | 11.89% | 33.14% | 10.27% | 5.91% |
| NBIX | Neurocrine Biosciences Inc | 44 | $8.81B | $93.21 | $122.38 | 31.29% | Buy | 9 | 19.43% | 10.39% | 59.08% | 38.57% |
| REGN | Regeneron Pharmaceuticals Inc | 33 | $61.22B | $574.61 | $622.91 | 8.41% | Buy | 11 | 8.26% | 4.30% | 41.58% | 28.02% |
| VRTX | Vertex Pharmaceuticals Inc | 33 | $52.18B | $201.58 | $262.19 | 30.07% | Buy | 17 | 8.97% | 2.07% | 37.99% | 28.16% |
| NVO | Novo Nordisk A S | 33 | $217.61B | $92.60 | N/A | N/A | Strong Buy | 1 | 7.32% | 7.64% | 101.62% | 42.04% |
| OVID | Ovid Therapeutics Inc | 22 | $252.92M | $3.73 | $6.00 | 60.86% | Buy | 4 | -5.71% | 40.23% | -22.92% | -21.35% |
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.